How to obtain immune bovine milk to strengthen the body against COVID-19

Physiologically, milk contains biocomponents that are highly protective against infections. In light of this, the AGR-149-Infectious Diseases group at the University of Cordoba's Department of Animal Health is doing research that focuses on cow's milk as a possible source of COVID-19 control. The results have been published, partially, in the journal Frontiers in Immunology.

This is possible due to "crossed immunity", and there is already evidence of the protection it provides, explained one of the principal investigators, Mari Carmen Borge. "It has been shown that the immune cells that the vaccinated animal generates against bovine coronavirus are capable of controlling other coronaviruses as well, such as SARS-CoV-2, which causes Covid-19".

Antonio Arenas, principal investigator on the project, spoke of the similarity that exists between Bovine Coronavirus (BCoV) and SARS-CoV-2 to explain the effectiveness of this technique. "There are a number of highly conserved structures of the virus that are similar in both viruses. In fact, both belong to the genus Betacoronavirus. Thus, cow's milk could have a total or partial blocking action against SARS-CoV-2".

In this way, these bovine antibodies could neutralize the virus in people who are already infected, or help prevent the disease in those who have not been vaccinated, or who have been, but have not developed immunity.

Thus, the aim is to come up with a supplement that would boost the immune system through a dairy preparation with a high level of antibodies, helping the system control infection through different immune pathways.

The animals from which the milk is extracted have been previously vaccinated with commercial BCoV vaccines, thus generating high levels of antibodies. However, the time when milk is most effective is just after a birth: "then the level of immunoglobulin in the milk increases - what is called colostrum - but it has a certain duration," Arenas added.

Now the scientific challenge is to be able to extend the colostrum period, and also to study how to always ensure the same level of antibodies in the final product. Plans call for it to be marketed in single-dose format as of September. "For this, we have to readjust the reproduction cycles of bovine farms in order to always maintain a set of animals with high antibodies", the researcher explained.

This dairy preparation, which anyone can consume, has already been tested on more than 300 people. Amongst them, no serious Covid-19 process has been detected. As soon as it goes on the market an observational test will be carried out. In any case, it will not be harmful to health, and it could become a natural resource providing people with a certain level of immunity.

There are other technological challenges: herd management, hygiene processes, conservation, packaging, marketing, medical, etc., that make this a holistic and complex project.

Arenas A, Borge C, Carbonero A, Garcia-Bocanegra I, Cano-Terriza D, Caballero J, Arenas-Montes A.
Bovine Coronavirus Immune Milk Against COVID-19.
Front Immunol. 2021 Mar 23;12:637152. doi: 10.3389/fimmu.2021.637152.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...